[SCHEDULE 13G/A] Scilex Holding Company Warrant SEC Filing

Rhea-AI Filing Summary

Oramed Pharmaceuticals Inc. filed an amendment to Schedule 13G disclosing beneficial ownership of 764,277 shares of Scilex Holding Co. common stock, representing 9.9% of the class. The filing clarifies that 762,277 of these shares are issuable upon exercise of warrants exercisable within 60 days of the filing date and that the total percent calculation used 6,955,697 outstanding shares reported by the issuer. Oramed reports sole voting and dispositive power over all 764,277 shares. The filing states the holdings were not acquired to change or influence control.

Positive

• Disclosure of material stake: Oramed reports a 9.9% beneficial ownership in Scilex, a material holding requiring disclosure
• Clarity on instrument type: Majority of the position (762,277 shares) is warrant-based and exercisable within 60 days, making timing transparent

Negative

• None.

Insights

Financial Analyst

TL;DR Oramed holds a near-10% economic interest via warrants and shares, a material disclosure but not an explicit control claim.

Oramed's reported 9.9% stake in Scilex is material for investors because it approaches a single-digit/near-10% ownership threshold that typically draws market attention. The position is primarily warrant-based (762,277 of the disclosed amount), with warrants exercisable within 60 days, which means potential share dilution and voting alignment could change if exercised. The filer asserts sole voting and dispositive power over the full amount and certifies the stake is not held to influence control.

Corporate Governance Expert

TL;DR Disclosure shows significant ownership concentration and governance implications if warrants are exercised.

The filing documents sole voting and dispositive authority for 764,277 shares representing 9.9% of the class based on the issuer's reported outstanding shares. From a governance perspective, holders near 10% may gain leverage in shareholder matters, particularly after warrant exercise. The certification states the position was not acquired to affect control, which is relevant to compliance with Schedule 13G filing standards. No group affiliations or transactions on behalf of others are reported.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Scilex Holding Co

(Name of Issuer)

Common Stock par value $0.0001 per share

(Title of Class of Securities)

80880W205

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 80880W205

1

Names of Reporting Persons

Oramed Pharmaceuticals Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 764,277.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 764,277.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

764,277.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Scilex Holding Co
(b)	Address of issuer's principal executive offices: 960 San Antonio Road, Palo Alto, California, 94303
Item 2.
(a)	Name of person filing: Oramed Pharmaceuticals Inc. (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: 1185 Avenue of the Americas, Third Floor, New York, NY 10036
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock par value $0.0001 per share
(e)	CUSIP No.: 80880W205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Rows 5 through 9 of the cover page for the Reporting Person and is incorporated herein by reference. The amount beneficially owned is comprised of 762,277 shares of common stock, par value $0.0001 per share ("Common Stock") of the Issuer issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13G has been filed with the Securities and Exchange Commission ("SEC").
(b)	Percent of class: The information required by Item 4(b) is set forth in Row 11 of the cover page for the Reporting Person and is incorporated herein by reference. The percent of class beneficially owned reported in Row 9 of the cover page for the Reporting Person is calculated based on 6,955,697 shares of Common Stock outstanding as of August 8, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025, plus 764,277 shares of Common Stock issuable upon exercise of warrants held by the Reporting Person that are exercisable within 60 days of the date on which this Schedule 13G has been filed with the SEC.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 764,277
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 764,277
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Oramed Pharmaceuticals Inc.

Signature:	/s/ Avraham Gabay
Name/Title:	Avraham Gabay, Chief Financial Officer
Date:	08/14/2025

FAQ

What percentage of Scilex (SCLXW) does Oramed Pharmaceuticals own?

Oramed reports beneficial ownership of 764,277 shares, representing 9.9% of Scilex's outstanding common stock as calculated in the filing.

How many of the reported shares are from warrants?

The filing states 762,277 shares are issuable upon exercise of warrants exercisable within 60 days of the filing.

Does Oramed have voting control over the shares?

Yes. Oramed reports sole voting power and sole dispositive power over all 764,277 shares.

Was the stake acquired to influence control of Scilex?

No. The certification in the filing states the securities were not acquired and are not held to change or influence control of the issuer.

What outstanding share count was used to calculate the percentage?

The percent was calculated using 6,955,697 outstanding shares reported by the issuer as of August 8, 2025.